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iDITORIAL COMMENT
enal Artery Stenosis: “Fortuitous
iagnosis,” Problematic Therapy*
arry A. Weinrauch, MD, FACC,
ohn A. D’Elia, MD
ambridge and Boston, Massachusetts
he carefully designed study by Buller et al. (1) in this issue
f the Journal suggests that 60 additional renal artery
tenosis (RAS) cases may be found per 1,000 cardiac
atheterizations (2,428 patients screened, 1,149 met at least
ne selection criteria, 298 excluded, resulting in 120 patients
eing newly diagnosed, more than half with stenoses
70%). How many we could find during noncardiac an-
iography or during the imaging of patients studied for
nrelated problems remains unstudied.
See page 1606
“Fortuitous diagnosis” of RAS has become commonplace,
ided by technical advancement (e.g., digital computed
omography, magnetic resonance reconstruction, color flow
uplex imaging). Recognition of the association among
arotid, coronary, and peripheral disease with RAS inevita-
ly leads to more attempts at renal vascular intervention,
articularly in patients over 70 years of age.
XPLORING THE BENEFITS OF REVASCULARIZATION
he goals for renal revascularization should be predefined.
oft end points, such as short-term arterial patency, stability
f renal function, or doses of antihypertensives, have been
he primary goal. Short-term arterial patency is an insuffi-
iently beneficial result to be a hard end point. Long term,
atency needs to be assured. We cannot depend upon such
onspecific, insensitive tests as serum creatinine to deter-
ine whether stents remain patent, renal function has
hanged, or hemodynamics altered.
Is reduction in number, dose, or type of antihypertensive
edicine required really an achievable result? Requirement
or less antihypertensive medication to achieve target blood
ressure goals would appear to confer benefit, especially if
orrisome side effects could be averted. A recent review
uoting eight studies of patients with RAS provides little
upport for greater effectiveness in blood pressure control or
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Departments of Medicine, Mount Auburn Hospital, Cambridge,
assachusetts; Joslin Diabetes Center, Boston, Massachusetts; Beth Israel Deaconess
edical Center, Boston, Massachusetts; and Harvard Medical School, Cambridge,oassachusetts.reservation of renal function when angioplasty is compared
ith drug therapy, particularly in individuals presumed to
ave small-vessel atherosclerosis, such as those with meta-
olic syndrome or previous cardiovascular complications (2).
n one of the studies reviewed, there was no difference in
enal function or level of blood pressure control for 106
AS patients randomized to drug therapy versus angio-
lasty and followed for one year. Although the number of
ntihypertensive drugs was lower in the instrumented
roup, this did not achieve statistical significance (3). In one
eta-analysis (4), 210 patients studied in randomized con-
rolled trials demonstrated insignificant differences in blood
ressure and renal function. In these trials, a decrease in
ntihypertensive agent use observed with angioplasty (with
r without stent) also was statistically insignificant. Experi-
nce has demonstrated that less than half of patients
ndergoing percutaneous transluminal renal angioplasty
enefit with respect to hypertension control or rescue of an
schemic organ (5,6).
Is a reduction in number, dose, or type of antihyperten-
ive medicine really a beneficial result? Revascularization has
een reported to reduce but not eliminate medication use.
he reduction of medicines used for hypertensive control
ay be deleterious in populations with the highest reported
ortality. Renin angiotensin system activation and beta-
drenergic blockade withdrawal by cessation of antihyper-
ensive medications adversely affect survival in patients with
ssociated vascular or renal disease. Thus, unless revascular-
zation improves the tolerance of beneficial medications, we
uestion whether their elimination represents an acceptable
ard end point.
Review of the literature found a high incidence of cardio-
ascular death with no evidence for prolongation of life after
enal revascularization. Renal artery stenosis patients in Swe-
en have a risk ratio of 5.7 for cardiovascular mortality when
ompared with an age-matched normal population (7). Two-
ear survival with medical therapy was 82% to 96% depending
pon the presence of bilateral, unilateral, or no significant
rterial obstructive disease and renal dysfunction in one study
rom Japan (8). A similar study in the U.K. lists a 31% five-year
urvival (9). In Germany, five-year survival after percutaneous
ransluminal renal angioplasty with stent was 89% to 96% for
atients with a serum creatinine2.5 mg/dl but as low as 30%
f the creatinine was above 2.5 mg/dl (10). In the U.S., even
ith the successful use of stents, patients with serum creatinine
f2 mg/dl had a four-year survival of only 25% (11). Patients
ith RAS that is associated with peripheral, carotid, or
oronary atherosclerosis or severe parenchymal disease have a
oor prognosis with or without renal revascularization. We
eed matched studies of long-term survival before we recom-
end RAS intervention in addition to medical therapy. Ex-
sting studies suffer from small size, insufficient duration (12),
r no control group (13).
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ercutaneous transluminal renal angioplasty has supplanted
ypass as a result of its benefits in terms of length of stay,
atient comfort, and decrease in morbidity. Morbidity is not
nsignificant. Percutaneous transluminal renal angioplasty is
ssociated with fairly high rates of major (5% to 8%) or
inor problems (10% to 15%), ranging from contrast
oxicity, hematoma, dissection, and renal embolism/infarct
eading to reduced kidney function or frank renal failure,
hich may require surgical intervention, to recurrent steno-
is, stent migration, or death (1% to 2%) (5,14,15). Studies
rom the U.S. and Australia demonstrated restenosis rates of
1% to 29% (16,17).
UTURE DIRECTIONS
he patients identified by Buller et al. (1) represent a special
igh-risk group defined by their need for coronary angiog-
aphy. In such patients, and in those defined by carotid and
eripheral vascular disease, cardiac, not renal, issues will
ecide mortality. Whether renal artery interventions would
id such patients in terms of quality or length of life remains
o be documented. The study by Buller et al. (1) designed to
dentify the prevalence of RAS in a carefully predefined
opulation should not be generalized to populations with
reater prevalence of renal disease, such as patients 80
ears of age with glomerulosclerosis and relatively silent
AS does not address the consequences of RAS in a
opulation.
How should we interpret this data? Perhaps the best
ramework is on the basis of the last 30 years of outcome
esearch in coronary arterial disease. Numerous studies have
emonstrated that the number of vessels involved, morphol-
gy of the obstruction, size of the distal vessel, and function
f the left ventricle strongly influence survival. Initial
nthusiasm for coronary artery surgery and eventually inter-
entional techniques has been tempered by the results of
arge studies demonstrating groups of patients who are not
ikely to derive benefit from aggressive revascularization.
emporary changes in myocardial function, such as stun-
ing and hibernation, have been recognized.
Similar concepts should be as apparent in native or
ransplanted kidneys. Although much literature exists for
enal biopsy and metabolism, there is no renal test similar to
oppler echocardiography to reliably assess functional im-
rovement. Perhaps as a result of this lack, studies suggest-
ng correction of RAS to preserve renal function have been
nconvincing. The failure of renal arterial bypass to cure
enovascular hypertension and glomerular/tubulointerstitial
brosis may be dependent upon previous parenchymal
amage, as is the case in the myocardium. No benefit from
enal revascularization occurs once the kidney loses glomer-
lar function, be it from infarct or irreversible medical renal
isease. A shrunken kidney, a cortically necrosed kidney, or
kidney proven by biopsy to have irreversible damage willenefit from revascularization as little as nonviable myocar-
ium. The renin-angiotensin system of a diseased kidney
glomerular or tubular) will have the same lack of benefit as
evascularization of coronaries in cardiomyopathy. Investi-
ators in this field are in need of a technology breakthrough,
uch as use of antioxidants (vitamins C and E), that may
reserve kidney function by inhibiting the inflammatory
rocess, which results in tubulointerstitial fibrosis in the
etting of RAS (18), providing the patient has been iden-
ified early enough in the course of ischemic injury.
In the group studied, the vast majority of renal angio-
rams would be unnecessary if clinicians used the criteria
isted: severe hypertension, unexplained renal dysfunction,
cute pulmonary hypertension with pulmonary edema, or
evere coronary atherosclerosis in patients scheduled to
ndergo elective coronary arterial studies (1). The study was
ot designed to determine whether patients with any of
hese criteria would benefit from renal revascularization.
Resistance index by Doppler ultrasound should be re-
uired before and after embarking upon intervention (19).
ither the ultrasound for renal cortical thickness or the
uclear scan for relative perfusion may identify kidneys
rreversibly scarred by prior ischemic disease. We believe
ndiscriminate testing for RAS or fortuitous documentation
f lesions leads to procedures laden with morbidity, high
ost, and mortality. The only benefit that should be ac-
epted as a reason for revascularization in a patient with
AS is one that can be measured. These would include
alvage of a single kidney (native or transplant) to avoid
ialysis, clinical consequence of inadequate blood pressure
ontrol (pulmonary edema, encephalopathy, acute renal
ailure, myocardial infarction) with multiple drug combina-
ions, or for prolongation of event-free life (should such
ventually be demonstrated). In the absence of randomized
ontrolled studies, clinicians would do well to follow the
dvice of Buller (1) by pursuing “long-term follow-up of this
ohort to determine the significance of RAS with respect to
pecific heart and kidney disease outcomes” in the manage-
ent of elderly high-risk patients.
eprint requests and correspondence: Dr. Larry A. Weinrauch,
21 Mount Auburn Street, Watertown, Massachusetts 02472.
-mail: lweinrauch@hms.harvard.edu.
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